These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32163180)

  • 21. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
    Muchtar E; Kumar SK; Magen H; Gertz MA
    Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The consultant's guide to smoldering multiple myeloma.
    Thorsteinsdottir S; Kristinsson SY
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
    Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
    Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
    Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H
    Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
    Sandecká V; Hájek R; Pour L; Špička I; Ščudla V; Gregora E; Radocha J; Walterová L; Kessler P; Zahradová L; Adamová D; Valentova K; Vonke I; Obernauerová J; Starostka D; Wróbel M; Brožová L; Jarkovský J; Mikulášová A; Říhová L; Ševčíková S; Straub J; Minařík J; Adam Z; Krejčí M; Král Z; Maisnar V;
    Eur J Haematol; 2017 Jul; 99(1):80-90. PubMed ID: 28384387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.
    Kumar S; Rajkumar SV; Jevremovic D; Kyle RA; Shifrin Y; Nguyen M; Husain Z; Alikhah A; Jafari A; Mai S; Anderson K; Louis S
    Am J Hematol; 2024 Aug; 99(8):1532-1539. PubMed ID: 38747543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding high-risk smoldering multiple myeloma.
    Kreiniz N; Gertz MA
    Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
    Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
    Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
    Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
    Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Melton LJ; Benson JT; Kumar S; Rajkumar SV
    Lancet Haematol; 2014 Oct; 1(1):e28-e36. PubMed ID: 25530988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How I approach smoldering multiple myeloma.
    Vaxman I; Gertz MA
    Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.